Skip to content

A randomized, 13-week study assessing the efficacy and safety of paliperidone palmitate and olanzapine in first-episode schizophrenic patients

A randomized, 13-week study assessing the efficacy and safety of paliperidone palmitate and olanzapi

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005304
Enrollment
Unknown
Registered
2014-10-11
Start date
2012-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenic

Interventions

1:Palm trees risperidone long-acting injection Paley

Sponsors

First Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
12 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) in accordance with the DSM-IV schizophrenia diagnosis standard; 2) patients younger than 60 years of age, men and women not limited; 3) must be in schizophrenia patients with acute attack stage, the PANSS score 70 points or more of the baseline period; 4) before using other antipsychotics patients need 4 weeks before the group maintain stability of the dose, patients with drug combination, types of antipsychotic drugs two or less; 5) CGI -s 4 points or more; 6) was not involved in diet or other weight loss program; 7) for families, for family members or guardian or legal representative of a written informed consent.

Exclusion criteria

Exclusion criteria: 1) pregnancy, nursing mothers, or planning a pregnancy; 2) have serious body disease, epilepsy, myocardial infarction, unstable angina and congestive heart failure, severe cirrhosis, severe acute or chronic renal failure, diabetes, aplastic anemia, and other serious nervous system, heart, liver, kidney, endocrine, blood system and other body disease.

Design outcomes

Primary

MeasureTime frame
cognitive function;the score of PANSS scale;PRL;insulin resistance index;Body mass index;

Countries

Zhejiang

Contacts

Public ContactHuang Manli
hml1208@sina.com+86 13957162975

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 8, 2026